Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
SpaceX launches Starlink satellites on its 150th Falcon 9 mission of the year - 2Without evidence, CDC changes messaging on vaccines and autism
- 3Kristin Cavallari was the teen queen bee of 'Laguna Beach.' Now she's a 'cringey' mom.
- 4Glamour Shots once ruled the mall. I went to one of the last ones standing.
- 5Vote In favor of Your Favored Web-based Visual depiction Administration
- 5 Eating routine Well disposed Snacks to Keep You Fulfilled
- Russia downs 16 drones heading for Moscow, mayor says
- DEA seizes 1.7 million counterfeit fentanyl pills in Colorado storage unit
- Oil Tanker Carrying Iraqi Cargo Seen Transiting Strait of Hormuz
- Chinese astronauts’ return to Earth delayed over fears spaceship damaged by debris
- The Strait of Hormuz Isn’t Just an Oil Problem, It’s Now a Food Problem
- 6 Monetary Arranging Administrations for Your Necessities
- CDC's upcoming vote on hepatitis B vaccine could impact childhood immunization
- 6 Web-based Lawful Administrations: Extensive Surveys and Elements
